Hidradenitis Suppurativa – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 6 PAGES: 27

More Info
									Hidradenitis Suppurativa – Pipeline Review, H1 2012




    Hidradenitis Suppurativa – Pipeline Review, H1 2012
                                                                                          Reference Code: GMDHC1704IDB
                                                                                            Publication Date: January 2012




Hidradenitis Suppurativa – Pipeline Review, H1 2012                                        GMDHC1704IDB / Pub January 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Hidradenitis Suppurativa – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Introduction......................................................................................................................................................................................... 4
    Global Markets Direct Report Coverage ........................................................................................................................................ 4
Hidradenitis Suppurativa Overview .................................................................................................................................................... 5
Therapeutics Development................................................................................................................................................................. 6
    An Overview of Pipeline Products for Hidradenitis Suppurativa .................................................................................................... 6
Hidradenitis Suppurativa Therapeutics under Development by Companies ....................................................................................... 8
Hidradenitis Suppurativa Therapeutics under Investigation by Universities/Institutes ........................................................................ 9
Late Stage Products ......................................................................................................................................................................... 10
    Comparative Analysis .................................................................................................................................................................. 10
Mid Clinical Stage Products.............................................................................................................................................................. 11
    Comparative Analysis .................................................................................................................................................................. 11
Hidradenitis Suppurativa Therapeutics – Products under Development by Companies................................................................... 12
Hidradenitis Suppurativa Therapeutics – Products under Investigation by Universities/Institutes .................................................... 13
Companies Involved in Hidradenitis Suppurativa Therapeutics Development.................................................................................. 14
    Abbott Laboratories ..................................................................................................................................................................... 14
Hidradenitis Suppurativa – Therapeutics Assessment ..................................................................................................................... 15
    Assessment by Monotherapy Products ....................................................................................................................................... 15
    Assessment by Route of Administration ...................................................................................................................................... 16
    Assessment by Molecule Type .................................................................................................................................................... 18
Drug Profiles..................................................................................................................................................................................... 20
    Humira - Drug Profile ................................................................................................................................................................... 20
         Product Description................................................................................................................................................................. 20
         Mechanism of Action ............................................................................................................................................................... 20
         R&D Progress ......................................................................................................................................................................... 20
    Enbrel - Drug Profile ...........................................................................................
								
To top